Atezolizumab: adverse event reports filed with FDA

19,768

reports as suspect product

0.1% of all reports · about 1,356 a year

1,887

reports, 12 months to June 2026

1,714 in the 12 months before

97.7%

marked serious by the reporter

89.9% across the class

19.2%

record death among outcomes, as reported

3,804 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Atezolizumab reports recording the termmedian drug in programmed death receptor-1 blocking antibody

1. Off label useused for a purpose or in a way not on the label6.7%1,322
2. Diarrhoealoose or frequent stools6%1,193
3. Deaththe patient died; cause not stated by this term5.7%1,131
4. Pyrexiafever5.4%1,076
5. Anaemialow red blood cells5.4%1,065
6. Disease progressionthe disease advanced5%982
7. Fatiguetiredness4.9%978
8. Nauseafeeling sick4%782
9. Pneumonialung infection3.9%772
10. Pneumonitis3.8%756
11. Hypothyroidismunderactive thyroid3.8%755
12. Decreased appetitereduced appetite3.6%717
13. Hypertensionhigh blood pressure3.4%674
14. Dyspnoeashortness of breath3.3%661
15. Febrile neutropeniafever with low white blood cells3.3%650
16. Thrombocytopenialow platelets3.2%633
17. Colitisinflamed bowel3%591
18. Vomitingbeing sick3%589
19. Neutropenialow neutrophils, a type of white blood cell2.9%582
20. Rashskin rash2.9%573
21. Astheniaweakness or lack of energy2.8%547
22. Acute kidney injurysudden loss of kidney function2.7%536
23. Constipationconstipation2.4%477
24. Intentional product use issuedeliberate use not as intended2.3%461
25. Platelet count decreasedlow platelet count2.3%459
26. Neutrophil count decreased2.3%455
27. Alanine aminotransferase increasedraised liver enzyme (ALT)2.3%450
28. Proteinuriaprotein in the urine2.2%434
29. Abdominal painstomach or belly pain2.1%418
30. Sepsisa severe body-wide response to infection2.1%417

Top 30 of 1,555 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 8 drugs in the programmed death receptor-1 blocking antibody class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 225,959 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 19.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 19,768 reports.

Drugs most often listed in the same reports

Other products listed in reports where Atezolizumab is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the programmed death receptor-1 blocking antibody class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Atezolizumab as a suspect or interacting product; reports listing it only as a concomitant medication (1,694) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.